Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.46 |
| ▸ | ITGAV | P06756 | 14/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27524220 | 1.00 | ITGB3 (0.46) | ITGB3ITGAVCNR1CNR2ITGA2B | |
| SCHEMBL4640844 | 0.91 | ITGB3 (0.48) | ITGB3ITGAVITGA2BITGB5HRH4 | |
| SCHEMBL6811091 | 0.90 | ITGB3 (0.53) | ITGB3ITGAVCNR1CNR2ITGA2B | |
| SCHEMBL4640097 | 0.89 | TDP1 (0.36) | ITGB3ITGAVCNR1CNR2HRH4 | |
| SCHEMBL7702988 | 0.86 | ITGB3 (0.44) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL4644035 | 0.86 | ITGB3 (0.44) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL6810270 | 0.84 | NPEPPS (0.34) | ITGB3ITGAVCNR1CNR2HRH4 | |
| SCHEMBL6016455 | 0.83 | HDAC6 (0.43) | ITGB3ITGAV | |
| SCHEMBL6016459 | 0.83 | HDAC6 (0.43) | ITGB3ITGAV | |
| SCHEMBL6805979 | 0.83 | CNR1 (0.41) | ITGB3ITGAVCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0853084-B1 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AG (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-6747016-B1 | TREATING OSTEOPOROSIS IN WARM-BLOODED ANIMALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-08 | — | — | US | disclosed |
| US-6723727-B1 | VITRONECTIN RECEPTOR ANTAGONISTS; INHIBITORS OF BONE RESORPTION; OSTEOPOROSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2004-04-20 | — | — | US | disclosed |
| EP-1196416-B1 | SUBSTITUTED PURINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA GMBH (DE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1196416-A1 | SUBSTITUTED PURINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001002399-A1 | SUBSTITUTED PURINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-01-11 | — | — | WO | disclosed |
| EP-1065208-A1 | Substituted purine derivatives as inhibitors of cell adhesion | Aventis Pharma Deutschland GmbH (DE) | 2001-01-03 | — | — | EP | disclosed |
| EP-0853084-A2 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-15 | — | — | EP | disclosed |